Vagal anandamide signaling via cannabinoid receptor 1 contributes to luminal 5-HT modulation of visceral nociception in rats
- 1 August 2014
- journal article
- Published by Wolters Kluwer Health in Pain
- Vol. 155 (8) , 1591-1604
Abstract
Serotonin (5-HT) plays pivotal roles in the pathogenesis of postinfectious irritable bowel syndrome (PI-IBS), and luminal 5-HT time-dependently modulates visceral nociception. We found that duodenal biopsies from PI-IBS patients exhibited increased 5-HT and decreased anandamide levels and that decreased anandamide was associated with abdominal pain severity, indicating a link between 5-HT and endocannabinoid signaling pathways in PI-IBS. To understand this, we investigated the role of endocannabinoids in 5-HT modulation of visceral nociception in a rat model. Acute intraduodenally applied 5-HT attenuated the visceromotor response (VMR) to colorectal distention, and this was reversed by the cannabinoid receptor 1 (CB1) antagonist AM251. Duodenal anandamide (but not 2-arachidonoylglycerol) content was greatly increased after luminal 5-HT treatment. This effect was abrogated by the 5-HT 3 receptor (5-HT3R) antagonist granisetron, which was luminally delivered to preferentially target vagal terminals. Chemical denervation of vagal afferents blocked 5-HT-evoked antinociception and anandamide release. Chronic luminal 5-HT exposure for 5 days increased baseline VMR and VMR post-5-HT (days 4 and 5). Duodenal levels of anandamide and N-acyl-phosphatidylethanolamine-specific phospholipase D (NAPE-PLD, the anandamide-synthesizing enzyme) protein gradually declined from day 1 to 5. The time-dependent effects of 5-HT were abolished by daily granisetron pretreatment. Daily pretreatment with CB1 agonists or anandamide from day 3 attenuated 5-HT-induced hyperalgesia. These data suggest that vagal 5-HT3R-mediated duodenal anandamide release contributes to acute luminal 5-HT-induced antinociception via CB1 signaling, whereas decreased anandamide is associated with hyperalgesia upon chronic 5-HT treatment. Further understanding of peripheral vagal anandamide signaling may provide insights into the mechanisms underlying 5-HT-related IBS.Keywords
This publication has 56 references indexed in Scilit:
- A critical re‐evaluation of the specificity of action of perivagal capsaicinThe Journal of Physiology, 2013
- CB1Receptors Mediate the Analgesic Effects of Cannabinoids on Colorectal Distension-Induced Visceral Pain in RodentsThe Journal of Neuroscience, 2009
- Serotonin Evokes Endocannabinoid Release and Retrogradely Suppresses Excitatory SynapsesJournal of Neuroscience, 2008
- Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia ☆Pain, 2007
- Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptorsNature Neuroscience, 2007
- Direct inhibition by cannabinoids of human 5‐HT3A receptors: probable involvement of an allosteric modulatory siteBritish Journal of Pharmacology, 2002
- Assembly and Cell Surface Expression of Homomeric and Heteromeric 5-HT3 Receptors: The Role of Oligomerization and Chaperone ProteinsMolecular and Cellular Neuroscience, 2002
- The synthetic cannabinoid WIN55,212‐2 attenuates hyperalgesia and allodynia in a rat model of neuropathic painBritish Journal of Pharmacology, 2001
- Acute effects of capsaicin on gastrointestinal vagal afferentsNeuroscience, 2000
- Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot studyGut, 1998